Alnylam PharmaceuticalsALNY
ALNY
About: Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Employees: 2,230
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 13 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
57% more first-time investments, than exits
New positions opened: 94 | Existing positions closed: 60
32% more repeat investments, than reductions
Existing positions increased: 233 | Existing positions reduced: 176
17% more call options, than puts
Call options by funds: $195M | Put options by funds: $166M
4.4% more ownership
Funds ownership: 94.55% [Q3] → 98.94% (+4.4%) [Q4]
4% more funds holding
Funds holding: 555 [Q3] → 578 (+23) [Q4]
10% less capital invested
Capital invested by funds: $33.4B [Q3] → $30B (-$3.36B) [Q4]
43% less funds holding in top 10
Funds holding in top 10: 7 [Q3] → 4 (-3) [Q4]
Research analyst outlook
13 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$268
2%
upside
Avg. target
$341
30%
upside
High target
$500
90%
upside
13 analyst ratings
11 positive
85%
2 neutral
15%
0 negative
0%
Morgan Stanley Michael Ulz 32% 1-year accuracy 6 / 19 met price target | 2%upside $268 | Equal-Weight Maintained | 11 Apr 2025 |
Needham Joseph Stringer 25% 1-year accuracy 28 / 112 met price target | 22%upside $320 | Buy Reiterated | 9 Apr 2025 |
HC Wainwright & Co. Patrick Trucchio 21% 1-year accuracy 40 / 187 met price target | 90%upside $500 | Buy Reiterated | 2 Apr 2025 |
Scotiabank Greg Harrison 24% 1-year accuracy 10 / 41 met price target | 30%upside $342 | Sector Outperform Maintained | 31 Mar 2025 |
Redburn Atlantic Joshua Smith 50% 1-year accuracy 1 / 2 met price target | 34%upside $353 | Buy Initiated | 31 Mar 2025 |
Financial journalist opinion
Based on 7 articles about ALNY published over the past 30 days
Neutral
Zacks Investment Research
1 day ago
Seeking Clues to Alnylam (ALNY) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Evaluate the expected performance of Alnylam (ALNY) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Neutral
Business Wire
2 days ago
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of its RNAi therapeutic vutrisiran for the treatment of wild type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). ATTR-CM is a debilitating, rapidly.
Negative
Zacks Investment Research
6 days ago
Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q1 Earnings Expected to Decline
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
Business Wire
1 week ago
Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2025 on Thursday, May 1, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2025 results as well as expectations for the future via conference call on Thursday, May 1, 2025 at 8:30 am ET. A live audio webcast of the.
Positive
Zacks Investment Research
2 weeks ago
Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last?
Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Neutral
Business Wire
4 weeks ago
Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Needham 24th Annual Virtual Healthcare Conference on Tuesday, April 8, 2025 at 11:45 am ET. A live audio webcast of the presentation will be available on the Investors section of the Company's website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event.
Neutral
CNBC Television
4 weeks ago
Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty
Paul Matteis, Stifel head of biotech research, joins 'The Exchange' to discuss the biotech trade under a new FDA amid the top vaccine official resigning.
Neutral
Business Wire
1 month ago
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the landmark HELIOS-B Phase 3 clinical trial, which evaluated vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) in a population representative of today's patients. Data were presented at the American College of Cardiology's Annual Scientific Session (ACC.25) held in Chicago, Illinois.
Neutral
Business Wire
1 month ago
FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration's (FDA) approval of Qfitlia™ (fitusiran), the sixth Alnylam-discovered RNAi therapeutic approved in the U.S., and the first and only therapeutic to lower antithrombin (AT), a protein that inhibits blood clotting, with the goal of promoting thrombin generation to rebalance hemostasis and prevent bleeds.
Neutral
GlobeNewsWire
1 month ago
siRNA Gene Silencing Market Landscape Report 2025: United States and Ireland Stand Out with 2 Major M&A Deals Worth $54.9 Billion, Alnylam Pharmaceuticals Leads the Way with 79 Trials
Dublin, March 28, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: siRNA gene silencing" report has been added to ResearchAndMarkets.com's offering.
Charts implemented using Lightweight Charts™